Company
Product name
Size (Fr)
Length (cm)
Cook
Flexor
9.5, 12.0, 14.0
13, 20, 28, 35, 45, 55
BARD
Aqua Guide
10/12, 10/14, 11/13, 11/15
25,, 35, 45, 55
Boston Scientific
Navigator
11/13, 13/15
28, 36, 46
Gyrus-ACMI
Uropass
12/14
24, 38, 54
Applied Medical
Forté
10/12, 12/14, 14/16
20, 28, 35, 45, 55
Prior to UAS deployment, two wires are placed into the upper tract under fluoroscopic guidance, one functioning as a safety wire and the other a working wire which is generally a stiff wire with a stainless steel core. The UAS is then moistened to ensure lubrication and advanced over the stiff wire under direct fluoroscopic guidance. It is important to ensure that the inner dilating cannula is securely engaged with the outer sheath during advancement to prevent ureteral injury from the exposed edge of the outer sheath. Once placed in satisfactory position, the inner dilating cannula and working wire are removed and the procedure performed.
While a UAS may be inserted without adjunctive maneuvers in the majority of endoscopic cases, it is not uncommon to encounter difficulty in passing the UAS. Harper et al. identified the following groups as at risk for conventional UAS insertion failure: young males with tight ureteral orifices, duplicated collecting systems, and small caliber ureters [9]. If UAS placement is difficult the following manipulations may be attempted. Ensure the stiff working wire is correctly positioned with adequate coil in the intrarenal collecting system. Then eliminate slack in the guidewire by appropriately tensioning the wire while making sure it is not withdrawn. These two manipulations assist in straightening the ureter thereby facilitating UAS acceptance. If the aforementioned manipulations do not permit UAS passage, gentle coaxial dilation with the internal obturator of the UAS or specially designed ureteral dilators may prove useful, but care should be taken to avoid applying excess sheer force that could lead to ureteral injury or avulsion [10]. Should the preceding measures fail, balloon dilation of the ureter may be performed. However, this may increase the risk of ureteral perforation. Finally, placement of an indwelling ureteral stent allows for passive ureteral dilation and successful UAS or ureteroscope insertion in 10–14 days.
In vitro and clinical studies can be used to predict how specific UASs may perform with regard to kinking and buckling. In a randomized trial comparing the 12/15 F Applied Access Forte XE (Applied Medical, Rancho Santa Margarita, California) to the 12/14 F Cook Flexor (Cook Urological, Spencer, Indiana) access sheath, Monga et al. analyzed the ease of placement and rate of device failure [3]. While there were no statistical differences between the two groups with regard to preoperative stenting or use of rigid ureteroscopy before UAS placement, the device failure rates were 44% and 0% for the Applied Medical and Cook UASs, respectively (p < 0.001). The device failures identified included buckling (25%), kinking (25%), and difficulty passing instruments (13%). The Cook sheath was also found to be superior with regard to ease of placement [3]. In a study evaluating the physical properties of next-generation UASs, Pedro and colleagues used an ex vivo model to better predict possible clinical failures [11]. Specifically, they evaluated the pressures at which buckling and kinking occurred, measured the coefficient of friction for each sheath during placement, and correlated that measurement to overall ease of placement. Testing included the Cook Flexor (Cook, 12/14 F × 35 cm), Gyrus-ACMI UroPass (ACMI, 12/14 F × 38 cm), Bard Aquaguide (Bard, 11/13 F × 35 cm), and Boston Scientific Navigator (BSCI-11, 11/13 F × 36 cm and BSCI-13, 13/15 F × 36 cm) UASs. The authors found that the Cook UAS performed best with regard to buckling. The Bard catheter was the most likely to kink, while the ACMI was superior with regard to kinking. There was no significant difference between the tested sheaths with regard to the coefficient of friction upon placement [11].
Intrarenal Pressures
Increased intrarenal pressures have long been a concern during ureteroscopy. Attempts to maintain good visualization may inadvertently raise intrarenal pressure and over-distend the renal pelvis, resulting in pyelosinus/pyelovenous back flow. The adverse effect of increased renal pelvic pressure has been documented in animal studies [12, 13]. At pressures exceeding 150 mmHg many pathologic changes begin to occur. These include, but are not limited to, submucosal edema, vasculitis, tubular vacuolization, and focal renal scarring. As pressures rise above 330 mmHg, rupture of the collecting system can occur. These are all real risks in the modern era of ureteroscopy with hand irrigation where pressures can exceed 400 mmHg [13].
The ability of the UAS to lower renal pressure has been demonstrated in several well-designed studies. Functioning as an open conduit into the kidney, it allows fluid to enter through the endoscope, and flow out through the sheath around the scope thereby decreasing renal pelvis pressure [5].
Landman and colleagues demonstrated this relationship using the en bloc urinary tract from cadaveric donors. In their study, lower pole percutaneous access with a 30 F sheath was gained into the kidney and a nephroscope was then advanced into the renal pelvis. Irrigant was infused through the nephroscope at varying rates, while the intrarenal pressure and irrigant flow rates were measured in a variety of ureteral drainage conditions. Ureteral drainage included the native ureter, a 6 F ureteral catheter, a 10/12 F × 35 cm UAS, 12/14 F × 35 cm UAS, and a 7 F occlusion balloon catheter. Importantly, intrarenal pressures were significantly lower while using both the 10/12 F and the 12/14 F UASs compared to the other conditions [5].
Ureteral access sheaths have also been shown to decrease renal pelvis pressures during ureteroscopy in a cadaveric model [6]. Using a percutaneous pressure monitor, the authors were able to record renal pelvis pressures while performing ureteroscopy with a 7.5 F flexible ureteroscope. The ureteroscopes were then introduced into the collecting system using a 35 cm UAS with varying diameters (10/12 F, 12/14 F, and 14/16 F) or unsheathed (control). The authors then delivered irrigant through the ureteroscope at pressures of 50, 100, or 200 mmHg while measuring intrarenal pressure and irrigant flow. Irrigant flow was higher in all of the UASs tested compared to controls. In all experimental conditions with a UAS in place, intrarenal pressure was noted to stay below 30 cm H2O. Notably, at low irrigant pressures (50 cmH2O), flow through each sheath was similar, but at increasing pressures the 12/14 F and 14/16 F sheaths had better pressure and flow characteristics than the 10/12 F sheath. They also noted that the 12/14 F sheath performed equally to 14/16 F sheath, concluding that the 12/14 F UAS optimizes pressure and flow characteristics while limiting UAS diameter [6].
This same relationship has proven true with in vivo human studies. Auge et al. identified five patients who required placement of a percutaneous nephrostomy tube after presenting to the emergency department for obstructing ureteral calculi [4]. The patients then underwent interval treatment with flexible ureteroscopy. After clearance of all stone fragments, the flexible scope was then advanced and pressures were recorded through the percutaneous nephrostomy tube while hand irrigation was performed in the renal pelvis, proximal ureter, mid and distal ureter. This was initially performed with the ureteroscope alone, and then with the aid of a UAS. The authors found that collecting system pressures were significantly lower with the use of a UAS at all locations by 57–75% (p < 0.05) [4].
Operative Time and Cost
By simplifying repeated access to the upper urinary tract, the UAS has proven beneficial in reducing operative times and cost [2, 3]. To address these issues Kourambas and colleagues prospectively analyzed a cohort of 59 patients presenting for endoscopy above the level of the iliac vessels [2]. The patients were randomized to ureteroscopy with or without the aid of a UAS. The authors utilized a 12/14 F hydrophilic coated UAS ranging from 20 to 35 cm depending on patient size, sex, and stone location. They found that the operative time was significantly lower in patients randomized to the use of a UAS (43 min vs. 53 min, p < 0.05). Despite having a higher total stone burden in these patients (13.7 mm vs. 10.1 mm, respectively), the stone free rates between these two groups were similar. The overall calculated saving, based on operating room time saved, was $350 per procedure. They also found significant time saving when the UAS was used for ureteral dilation, and calculated an average saving of $700 per dilation when considering the cost of the balloon dilation system [2].
UAS use may further reduce overall costs by reducing wear and tear on endoscopic equipment. Technologic advancement in materials science has permitted the miniaturization of ureteroscopes while concurrently increasing active range of motion and improving visualization. However, modern ureteroscopes are vulnerable to damage and the need for costly repairs, in previous studies requiring repair on average every 6–15 uses [14]. Not only is the monetary cost of these repairs high, but it can also lead to unnecessary delays in the operating room and possibly unexpected complications. The UAS decreases wear and tear on modern ureteroscopes by reducing axial forces on the ureteroscope as well as trauma to the working channel from repetitive backloading over a guidewire. With the use of a UAS, authors have shown that ureteroscopes could be used on average 27.5 times between repairs, thereby reducing the cost of ureteroscopy [15].
Stone Free Rates
Surgeons have postulated that UASs improve stone free rates following ureteroscopy by allowing for passive irrigation of stone fragments as well as quicker access to the upper collecting system. With this in mind, it is reasonable to consider the retrospective data available. Previously published reports have listed the stone free rates for ureteroscopy without the aid of a UAS ranging between 72 and 84% [16–20], and from 77 to 86% with the use of a UAS [2, 21].
To date, L’Esperance and colleagues have published the only study directly evaluating the effect of UAS utilization on stone free rates following ureteroscopy [8]. Following a retrospective review of their clinical database, they identified a total of 256 ureteroscopic procedures performed for renal calculi, 173 of which were performed with the use of a UAS. Demographic data, stone burden, and stone location were similar between groups. The authors found that overall stone free rates were significantly improved in those patients in whom a UAS was utilized 79% vs. 67%, p = 0.042 [8]. It should be noted that while UAS use seems to facilitate ureteroscopy and possibly improve stone free rates, no level-one evidence exists to support or refute this claim.
Postoperative Course Following UAS Utilization
Ureteral stents are associated with symptoms such as frequency, dysuria, and flank pain [22], and for this reason efforts have been made to identify patients who do not require a ureteral stent post operatively. While symptoms are minimized with proper stent positioning [23, 24], they are still a significant cause of patient morbidity and their use has been discouraged following uncomplicated ureteroscopy [12, 25]. Post-operative pain, urinary symptoms, and narcotic use are lower in patients without ureteral stents, but these studies were performed on patients who did not require ureteral dilation [12, 25]. In a retrospective review, Rappaport and colleagues analyzed their data on 161 consecutive patients treated with ureteroscopy by evaluating the impact of stent vs. no stent on unplanned ER visits. In their cohort, 37% of patients treated with a UAS vs. 14% without a UAS returned to the ER for evaluation if a ureteral stent was not placed after the procedure (p = 0.04). They concluded that use of a UAS precluded uncomplicated ureteroscopy and would therefore warrant placement of a ureteral stent [26].